GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL (NASDAQ: GRAL) has announced the granting of equity awards in the form of restricted stock units (RSUs) to 15 newly hired non-executive employees. The inducement grants, totaling 108,450 shares of GRAIL's common stock, were awarded under the company's Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs feature a four-year vesting schedule, with 25% vesting on February 28, 2026, and subsequent annual vestings on the same date, contingent upon continued employment with GRAIL or its subsidiaries.
GRAIL (NASDAQ: GRAL) ha annunciato l'assegnazione di premi azionari sotto forma di unit脿 azionarie vincolate (RSU) a 15 nuovi dipendenti non esecutivi. I premi di induzione, per un totale di 108.450 azioni ordinarie di GRAIL, sono stati concessi nell'ambito del Piano di Incentivazione Azionaria di Induzione dell'azienda, in conformit脿 con la Regola di Quotazione Nasdaq 5635(c)(4).
Le RSU presentano un programma di maturazione di quattro anni, con il 25% che matura il 28 febbraio 2026, e successivi diritti annuali di maturazione nella stessa data, a condizione di un'occupazione continuativa con GRAIL o le sue filiali.
GRAIL (NASDAQ: GRAL) ha anunciado la concesi贸n de premios en forma de unidades de acciones restringidas (RSUs) a 15 nuevos empleados no ejecutivos. Las concesiones de inducci贸n, que suman un total de 108,450 acciones ordinarias de GRAIL, se otorgaron bajo el Plan de Incentivos de Capital de Inducci贸n de la empresa, en cumplimiento con la Regla de Cotizaci贸n 5635(c)(4) de Nasdaq.
Las RSUs tienen un programa de adquisici贸n de cuatro a帽os, con un 25% que se adquiere el 28 de febrero de 2026, y adquisiciones anuales posteriores en la misma fecha, siempre que contin煤e el empleo con GRAIL o sus filiales.
GRAIL (NASDAQ: GRAL)鞚� 15氇呾潣 鞁犾瀰 牍勳瀯鞗� 歆侅洂鞐愱矊 鞝滍暅 欤检嫕 雼渼(RSU) 順曧儨鞚� 欤检嫕 氤挫儊鞚� 攵�鞐暅雼り碃 氚滍憸頄堨姷雼堧嫟. 齑� 108,450欤检潣 GRAIL 氤错喌欤缄皜 韽暔霅� 鞙犾澑 氤挫儊鞚� Nasdaq 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 須岇偓鞚� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 靾橃棳霅橃棃鞀惦媹雼�.
搁厂鲍电� 4雲勳潣 旆摑 鞚检爼鞚� 臧�歆�瓿� 鞛堨溂氅�, 2026雲� 2鞗� 28鞚检棎 25%臧� 旆摑霅橁碃, 鞚错泟 毵る厔 臧欖潃 雮犾鞐� 旆摑鞚� 鞚措（鞏挫氅�, GRAIL 霕愲姅 攴� 鞛愴殞靷棎靹� 瓿勳啀 攴茧頃挫暭 頃╇媹雼�.
GRAIL (NASDAQ: GRAL) a annonc茅 l'octroi de r茅compenses en actions sous forme d'unit茅s d'actions restreintes (RSUs) 脿 15 nouveaux employ茅s non ex茅cutifs. Les attributions d'incitation, totalisant 108 450 actions ordinaires de GRAIL, ont 茅t茅 accord茅es dans le cadre du Plan d'Incitation en Actions de l'entreprise, conform茅ment 脿 la R猫gle de Cotation Nasdaq 5635(c)(4).
Les RSUs pr茅sentent un calendrier d'acquisition de quatre ans, avec 25 % qui sera acquis le 28 f茅vrier 2026, et des acquisitions annuelles subs茅quentes 脿 la m锚me date, sous r茅serve d'un emploi continu avec GRAIL ou ses filiales.
GRAIL (NASDAQ: GRAL) hat die Gew盲hrung von Aktienauszeichnungen in Form von Restricted Stock Units (RSUs) an 15 neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Die Anreizvergaben, die insgesamt 108.450 Aktien von GRAILs Stammaktien umfassen, wurden im Rahmen des Unternehmensplans zur Anreizaktienverg眉tung gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4) vergeben.
Die RSUs haben einen vierj盲hrigen Vesting-Zeitplan, wobei 25% am 28. Februar 2026 f盲llig werden, gefolgt von j盲hrlichen Vestings am selben Datum, vorausgesetzt, dass das Arbeitsverh盲ltnis mit GRAIL oder seinen Tochtergesellschaften fortgesetzt wird.
- None.
- None.
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over聽an approximately four year period, with
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit .
View original content to download multimedia:
SOURCE GRAIL, Inc.
FAQ
How many GRAL shares were granted as RSUs in the February 2025 inducement awards?
What is the vesting schedule for GRAL's February 2025 inducement RSUs?
Why did GRAIL (GRAL) issue these inducement grants?
Under which plan were GRAL's February 2025 inducement RSUs granted?
